EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Recruitment Status
RECRUITING
(See Contacts and Locations)Verified March 2026 by Mediar Therapeutics
Sponsor
Mediar Therapeutics
Information Provided by (Responsible Party)
Mediar Therapeutics
Clinicaltrials.gov Identifier
NCT07287670
Other Study ID Numbers:
MTX-474-S201
First Submitted
November 17, 2025
First Posted
December 16, 2025
Last Update Posted
June 3, 2026
Last Verified
March 2026

ClinicalTrials.gov processed this data on June 2026. Link to the current ClinicalTrials.gov record .

History of Changes

Study Details

Study Description

Participants with dcSSc who meet the study's inclusion and exclusion criteria will be randomly assigned in a 3:2 ratio to receive MTX-474 or a matching placebo by intravenous (IV) infusion. Concomitant use of one of the approved dcSSc therapies (immunosuppressive therapy, systemic glucocorticoids or other antifibrotic agents) is permitted under certain criteria. Participants randomized to the MTX-474 arm of the study will receive an IV infusion every 4 weeks, beginning at Day 0 and ending at Week 20. The End of Treatment Visit will occur at Week 24, and a Safety Follow-Up Visit will occur at Week 28, 8 weeks after the final infusion. mRSS assessments will occur at Screening, Baseline, and at all subsequent treatment visits up to and including Week 24. Spirometry will be performed at screening and Weeks 12. HRCT will be performed at screening and week 24. DLCO will be performed at Screening. Skin biopsies will be performed at Baseline and Week 12. Participants will have blood drawn for safety assessment and to assess Ephrin receptor levels at Screening, Baseline and every 4 weeks until Week 28. Blood will be drawn for serum PK analyses relative to the first and last doses of MTX-474.

Condition or DiseaseIntervention/Treatment
Diffuse Cutaneous Systemic Sclerosis
Biological: MTX-474Other: Placebo

Study Design

Study TypeInterventional
Actual Enrollment85 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingQuadruple
Primary PurposeTreatment
Official TitleA Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Study Start DateApril 15, 2026
Actual Primary Completion Date2yrs 5mos from now
Actual Study Completion Date2yrs 5mos from now

Groups and Cohorts

Group/CohortIntervention/Treatment
MTX-474
MTX-474
Biological: MTX-474
Dosage level: 4 mg/kg Unit dose strength: 50mg/ml MTX-474 is a human immunoglobulin G1 (IgG1) monoclonal antibody that binds the human EphrinB2 with high specificity and high affinity. MTX-474 is being developed as a therapy for patients with systemic sclerosis (SSc).
Placebo
Placebo
Other: Placebo
Placebo

Outcome Measures

Primary Outcome Measures
  1. Change from baseline in Modified Rodnan Skin Score (mRSS)
    Mean change from baseline to week 24 in the modified Rodnan Skin Score, a clinician-assessed measure of skin thickness across 17 body areas. Unit of measure: Score (range 0-51)
Secondary Outcome Measures
  1. Proportion of participants with a gene signature response in skin biopsy
    Proportion of participants in each arm (MTX-474 and placebo) demonstrating a dcSSc gene expression signature response on skin biopsy at Week 12. Unit of Measure: Participants (%)
  2. Number of participants with clinically significant findings on physical examination, vital signs, and clinical laboratory tests
    Number of participants with clinically significant findings on physical examination, vital signs, and clinical laboratory tests Unit of Measure: Participants (%)
  3. Number of participants with dose interruptions or treatment discontinuations due to adverse events
    Number of participants with dose interruptions or treatment discontinuations due to adverse events Unit of Measure: Participants (%)
  4. Safety and tolerability of MTX-474 in participants with dcSSc: Number of participants with treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs)
    Incidence, seriousness, and severity of TEAEs and TRAEs as determined by investigator assessment. Unit of measure: Participants (%)
  5. Serum concentration of MTX-474 at sparse PK time points
    Serum MTX-474 concentrations collected at predefined sparse PK time points to support population pharmacokinetic (popPK) analysis Unit of Measure: ng/mL
  6. Clearance (CL) of MTX-474
    Clearance of MTX-474 calculated from serial PK sampling using noncompartmental analysis Unit of Measure: L/hour
  7. Terminal elimination half-life (t½) of MTX-474
    Terminal elimination half-life of MTX-474 derived from serial PK sampling. Unit of Measure: Hours
  8. Area under the plasma concentration-time curve (AUC) of MTX-474
    AUC of MTX-474 calculated from serial PK sampling using noncompartmental analysis. Unit of Measure: ng·h/mL

Eligibility Criteria

Ages Eligible for Study(Adult, Older Adult)
Sexes Eligible for StudyAll
Accepts Healthy VolunteersNo
Inclusion Criteria
1. Diagnosis of diffuse cutaneous systemic sclerosis, classified according to 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2. Participant is either: 1. Within 2 years of their first non-Raynaud's symptom and their mRSS is \>7; OR 2. \>2 and ≤5 years from their first non-Raynaud's symptom, their mRSS is between 10 and 30, they are negative for the RNA polymerase 3 autoantibody, and (1) they have never had any previous spontaneous improvement in skin thickening of ≥4 points by mRSS on exams performed by the same clinician, or (2) they were never clinically noted to have a meaningful spontaneous reduction in skin thickness if mRSS was never done; OR 3. \>5 and ≤10 years from their first non-Raynaud's symptom, their mRSS is between \>15 and ≤25, they are negative for the RNA polymerase 3 autoantibody, and (1) they have never had any previous spontaneous improvement in skin thickening of ≥4 points by mRSS, or (2) were never clinically noted to have a meaningful spontaneous reduction in skin thickness if mRSS was never done. 3. Participant is ≥18 years of age at time of signing the ICF. 4. Able to understand the study and provide a signed, written ICF 5. Able to read and understand the language of the ICF and other study-related materials 6. Forced vital capacity (FVCpp) of ≥45 pp10 7. Have diffusing capacity of the lungs for carbon monoxide (DLCO) of ≥30 percent predicted at Screening 8. Willing and able to complete all protocol-required study visits and procedures 9. Participants of childbearing potential must have a negative serum pregnancy test at Screening. 10. All participants with reproductive potential must agree to use and follow medically approved, highly effective methods of contraception during treatment and until 5 half-lives or 125 days after the last dose, whichever is longer
Exclusion Criteria
1. Concomitantly have another serious medical illness, which, in the opinion of the Investigator, would interfere with the participant's ability to complete the study 2. Participant is currently on immunosuppressive therapy, systemic glucocorticoids or other antifibrotic agents detailed as follows: 1. Immunosuppresive agents: Cyclophosphamide (IV or oral if used in the 6 months prior to Screening), calcineurin inhibitors (if used in the 30 days prior to Screening), azathioprine (if used in the 30 days prior to Screening), Janus-kinase inhibitors (if used in the 30 days prior to Screening), rituximab (if used in the 6 months prior to Screening), tocilizumab (if used in the 60 days prior to Screening) or any other biologic Disease-Modifying Antirheumatic Drugs (DMARD, if used in the last 30 days or 3 half-lives prior to Screening, whichever is longer) 2. Antifibrotic agents: nintedanib or pirfenidone (if used in the 30 days prior to Screening). Also, exclusionary if used within 3 months of Screening are tyrosine-kinase inhibitors with recognized anti-fibrotic activity (imatinib, nilotinib, etc.) 3. Systemic glucocorticoids: equivalent doses of prednisone greater than 10 mg/day (≤10 mg/day allowed). Has received any pulse intramuscular (IM) or intravenous (IV) steroid within 1 month of Screening 4. Other agents: i. mycophenolate mofetil unless on a stable dose for at least 6 months prior to Screening and there are no plans to adjust the dose during the study; ii. mycophenolic acid unless on a stable dose for at least 6 months prior to Screening and there are no plans to adjust the dose during the study; iii. hydroxychloroquine unless on a stable dose for at least 3 months prior to Screening and there are no plans to adjust the dose during the study; and iv. methotrexate unless on a stable dose for at least 3 months prior to Screening and there are no plans to adjust the dose during the study. 3. Previous or planned hematopoietic stem cell or solid organ transplantation 4. Previous treatment with chimeric antigen receptor (CAR)-T/CAR-NK therapy 5. Clinically significant PAH as determined by the Investigator at, or prior to first day of dosing (Baseline) 6. Current use of PAH medication (endothelin receptor antagonists, prostacyclin analogues, soluble guanylate cyclase stimulators) excluding calcium channel blockers and phosphodiesterase-5 inhibitors 7. Pregnant or currently breastfeeding 8. Aspartate transaminase (AST) or alanine transaminase (ALT) \>2.0 upper limit of normal 9. Creatinine clearance \<45mL/min 10. History of myocardial infarction, angina or congestive heart failure 11. International normalized ratio \>2 or partial thromboplastin time \>1.5 × upper limit of normal 12. Active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C 13. History of clinically significant thrombotic event within 12 months prior to Screening 14. Positive anticentromere antibody 15. Systemic sclerosis renal crisis within 12 months prior to Screening 16. Confirmed diagnosis of overlap syndrome, systemic lupus erythematosus with anti-double strand (ds)DNA antibody, rheumatoid arthritis with anti-cyclic citrullinated peptide (anti-CCP) antibody, or systemic sclerosis mimics (eosinophilic fasciitis, scleromyxedema) at the time of inclusion in the study 17. Known malignancy or history of malignancy within 5 years of Screening other than non-melanoma skin cancer and in situ cervical cancer 18. Major surgery within 8 weeks prior to Screening or planned surgery during study period 19. Unable to routinely access veins for blood draws and IV infusions 20. Currently receiving another experimental agent or participating in another clinical trial. If a participant has recently received another experimental agent, then the last dose must have been at least 5 half-lives or 30 days (whichever is longer) prior to Screening 21. History of myocardial infarction, angina or congestive heart failure

Contacts and Locations

Sponsors and CollaboratorsMediar Therapeutics
Locations
EncompaSSc site in Newport Beach, CA 92663 | Newport Beach California, United States, 92663EncompaSSc site in Clearwater, FL 33765 | Clearwater Florida, United States, 33765EncompaSSc site in Tampa, FL | Tampa Florida, United States, 33606EncompaSSc site in Baltimore, MD | Baltimore Maryland, United States, 21224EncompaSSc site in Boston, MA | Boston Massachusetts, United States, 02118EncompaSSc site in Dallas, TX | Dallas Texas, United States, 75246